PDF(Pubmed)
Abstract：
Gastrointestinal malignancies are one of the major worldwide health concerns. In the present review, we have assessed the plausible therapeutic implication of Ursolic Acid (UA) against gastrointestinal cancer. By modulating several signaling pathways critical in cancer development, UA could offer anti-inflammatory, anti-proliferative, and anti-metastatic properties. However, being of low oral bioavailability and poor permeability, its clinical value is restricted. To deliver and protect the drug, liposomes and polymer micelles are two UA nanoformulations that can effectively increase medicine stability. The use of UA for treating cancers is safe and appropriate with low toxicity characteristics and a predictable pharmacokinetic profile. Although the bioavailability of UA is limited, its nanoformulations could emerge as an alternative to enhance its efficacy in treating GI cancers. Further optimization and validation in the clinical trials are necessary. The combination of molecular profiling with nanoparticle-based drug delivery technologies holds the potential for bringing UA to maximum efficacy, looking for good prospects with GI cancer treatment.
摘要：
胃肠道恶性肿瘤是全球主要的健康问题之一。在本次审查中，我们评估了熊果酸(UA)对胃肠道肿瘤的合理治疗意义.通过调节几种在癌症发展中至关重要的信号通路，UA可以提供抗炎，抗增殖，和抗转移特性。然而,口服生物利用度低，渗透性差，其临床价值受到限制。为了提供和保护药物，脂质体和聚合物胶束是两种可以有效增加药物稳定性的UA纳米制剂。使用UA治疗癌症是安全和适当的,具有低毒性特征和可预测的药代动力学特征。虽然UA的生物利用度是有限的,其纳米制剂可能会成为一种替代方案，以提高其治疗胃肠道癌症的疗效。在临床试验中进一步优化和验证是必要的。分子谱分析与基于纳米颗粒的药物递送技术的结合具有使UA达到最大疗效的潜力。寻找胃肠道癌症治疗的良好前景。
